medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2020, Number 1

<< Back Next >>

Medicina & Laboratorio 2020; 24 (1)

Genomic, transcriptomic, and diagnostic features of Down syndrome

Díaz-Hernández DJ, Torres-Gómez IP, Arango-Martínez AM, Manrique-Hernández RD, Gallo-Bonilla JE

Language: Spanish
References: 60
Page: 37-56
PDF size: 300.62 Kb.


ABSTRACT

Down syndrome is caused by the presence of a third copy of chromosome 21 and was first described by Jean-Etienne-Dominique in 1838, and later by John Langdon Haydon Down in 1866, while working as a medical superintendent in the Royal Earlswood Asylum. Since, the scientific community has placed great efforts in trying to elucidate different influencing features in the nature of this condition that determine their incidence and risk factors. In addition, especial attention has been given to the genes involved in this disease, the genotype-phenotype relationship, the expression of the phenotype, the variability of the genetic material and the transcriptional consequences that are produced by having a third copy, either partial or total, of chromosome 21. Additionally, efforts have been invested in identifying biomarkers and designing noninvasive prenatal methodologies that are highly efficient for a better diagnosis of Down syndrome, in order to reduce its negative impact in pregnant mothers, by providing them with neutral and accurate information about life with a child with Down syndrome, as well as providing the autonomy in the decision to continue their pregnancy.


REFERENCES

  1. Cammarata-Scalisi F, Da Silva G, Cammarata- Scalisi G, Sifuentes A. Historia del síndrome de Down. Un recuento lleno de protagonistas. Can Pediatr 2010;34 157-159.

  2. Wang Y, Zhang X, Ling B, He C, Xia Q, Chen F, et al. Molecular detection of trisomy 21 by bicolor competitive fluorescent PCR. J Clin Lab Anal 2013;27:245-248.

  3. Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. “Down syndrome: an insight of the disease”. J Biomed Sci 2015;22:41.

  4. Sierra-Romero MDC, Navarrete-Hernandez E, Canun-Serrano S, Reyes-Pablo AE, Valdes- Hernandez J. [Prevalence of Down syndrome using certificates of live births and fetal deaths in Mexico 2008-2011]. Bol Med Hosp Infant Mex 2014;71:292-297.

  5. Kamyab AR, Shahrokhi F, Shamsian E, Hayat Nosaied M, Dibajnia P, Hashemi M, et al. Determination of sensitivity and specificity of a novel gene dosage assay for prenatal screening of trisomy 21 syndrome. Clin Biochem 2012;45:267-271.

  6. Bushman DM, Kaeser GE, Siddoway B, Westra JW, Rivera RR, Rehen SK, et al. Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer’s disease brains. Elife 2015;4.

  7. Patel A, Yamashita N, Ascano M, Bodmer D, Boehm E, Bodkin-Clarke C, et al. RCAN1 links impaired neurotrophin trafficking to aberrant development of the sympathetic nervous system in Down syndrome. Nat Commun 2015;6:10119.

  8. Souchet B, Latour A, Gu Y, Daubigney F, Paul JL, Delabar JM, et al. Molecular rescue of DYRK1A overexpression in cystathionine beta synthase-deficient mouse brain by enriched environment combined with voluntary exercise. J Mol Neurosci 2015;55:318-323.

  9. Al-Biltagi M. Down syndrome from epidemiologic point of view. EC Paediatrics 2015;2:82-91.

  10. Delabar JM, Theophile D, Rahmani Z, Chettouh Z, Blouin JL, Prieur M, et al. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1993;1:114-124.

  11. Osato M, Ito Y. Increased dosage of the RUNX1/ AML1 gene: a third mode of RUNX leukemia? Crit Rev Eukaryot Gene Expr 2005;15:217-228.

  12. Xavier AC, Ge Y, Taub JW. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn 2009;11:371-380.

  13. Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down’s syndrome. Nature 2008;451:73-75.

  14. Baek K-H, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, et al. Down syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1. Nature 2009;459:1126-1130.

  15. Salemi M, Barone C, Romano C, Salluzzo R, Caraci F, Cantarella RA, et al. Pericentrin expression in Down’s syndrome. Neurol Sci 2013;34:2023-2025.

  16. Antonarakis SE. Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet 2017;18:147-163.

  17. Olmos-Serrano JL, Kang HJ, Tyler WA, Silbereis JC, Cheng F, Zhu Y, et al. Down syndrome developmental brain transcriptome reveals defective oligodendrocyte differentiation and myelination. Neuron 2016;89:1208-1222.

  18. Prandini P, Deutsch S, Lyle R, Gagnebin M, Delucinge Vivier C, Delorenzi M, et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am J Hum Genet 2007;81:252-263.

  19. Lim JH, Kim SY, Han JY, Kim MY, Park SY, Ryu HM. Comprehensive investigation of DNA methylation and gene expression in trisomy 21 placenta. Placenta 2016;42:17-24.

  20. Megarbane A, Ravel A, Mircher C, Sturtz F, Grattau Y, Rethore MO, et al. The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet Med 2009;11:611-616.

  21. Sinet PM, Theophile D, Rahmani Z, Chettouh Z, Blouin JL, Prieur M, et al. Mapping of the Down syndrome phenotype on chromosome 21 at the molecular level. Biomed Pharmacother 1994;48:247-252.

  22. Pritchard MA, Kola I. The “gene dosage effect” hypothesis versus the “amplified developmental instability” hypothesis in Down syndrome. J Neural Transm Suppl 1999;57:293-303.

  23. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York; McGraw-Hill. 2001.

  24. Shapiro BL. Down syndrome-a disruption of homeostasis. Am J Med Genet 1983;14:241-269.

  25. Olson LE, Roper RJ, Sengstaken CL, Peterson EA, Aquino V, Galdzicki Z, et al. Trisomy for the Down syndrome ‘critical region’ is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet 2007;16:774-782.

  26. Pelleri MC, Gennari E, Locatelli C, Piovesan A, Caracausi M, Antonaros F, et al. Genotype- phenotype correlation for congenital heart disease in Down syndrome through analysis of partial trisomy 21 cases. Genomics 2017;109:391-400.

  27. FitzPatrick DR, Ramsay J, McGill NI, Shade M, Carothers AD, Hastie ND. Transcriptome analysis of human autosomal trisomy. Hum Mol Genet 2002;11:3249-3256.

  28. Chrast R, Scott HS, Papasavvas MP, Rossier C, Antonarakis ES, Barras C, et al. The mouse brain transcriptome by SAGE: differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. Genome Res 2000;10:2006-2021.

  29. Mao R, Wang X, Spitznagel EL, Jr., Frelin LP, Ting JC, Ding H, et al. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol 2005;6:R107.

  30. Thomas JW, Touchman JW, Blakesley RW, Bouffard GG, Beckstrom-Sternberg SM, Margulies EH, et al. Comparative analyses of multispecies sequences from targeted genomic regions. Nature 2003;424:788-793.

  31. Antonarakis SE, Epstein CJ. The challenge of Down syndrome. Trends Mol Med 2006;12:473- 479.

  32. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-487.

  33. Lo YM. Fetal DNA in maternal plasma: biology and diagnostic applications. Clin Chem 2000;46:1903-1906.

  34. Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009;201:472 e471-477.

  35. Sifakis S, Koukou Z, Spandidos DA. Cell-free fetal DNA and pregnancy-related complications (review). Mol Med Rep 2015;11:2367-2372.

  36. Hyland CA, Millard GM, O’Brien H, Schoeman EM, Lopez GH, McGowan EC, et al. Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. Pathology 2017;49:757-764.

  37. Chen CP, Wang YL, Chern SR, Wu PS, Chen YN, Chen SW, et al. Prenatal diagnosis and molecular cytogenetic characterization of lowlevel true mosaicism for trisomy 21 using uncultured amniocytes. Taiwan J Obstet Gynecol 2016;55:285-287.

  38. Allyse M, Minear MA, Berson E, Sridhar S, Rote M, Hung A, et al. Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health 2015;7:113-126.

  39. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol 2013;42:15-33.

  40. Gray KJ, Wilkins-Haug LE. Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening. Pediatr Radiol 2018;48:461-470.

  41. Papageorgiou EA, Fiegler H, Rakyan V, Beck S, Hulten M, Lamnissou K, et al. Sites of differential DNA methylation between placenta and peripheral blood: molecular markers for noninvasive prenatal diagnosis of aneuploidies. Am J Pathol 2009;174:1609-1618.

  42. Patsalis PC. A new method for non-invasive prenatal diagnosis of Down syndrome using MeDIP real time qPCR. Appl Transl Genom 2012;1:3-8.

  43. Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC. Fetalspecific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med 2011;17:510-513.

  44. Kamhieh-Milz J, Moftah RF, Bal G, Futschik M, Sterzer V, Khorramshahi O, et al. Differentially expressed microRNAs in maternal plasma for the noninvasive prenatal diagnosis of Down syndrome (trisomy 21). Biomed Res Int 2014;2014:402475.

  45. Liao JM, Zhou X, Zhang Y, Lu H. MiR-1246: a new link of the p53 family with cancer and Down syndrome. Cell Cycle 2012;11:2624-2630.

  46. Brás A, Rodrigues AS, Gomes B, Rueff J. Down syndrome and microRNAs. Biomed Rep 2018;8:11-16.

  47. Tóth T, Findlay I, Papp C, Tóth-Pál E, Marton T, Nagy B, et al. Prenatal detection of trisomy 21 and 18 from amniotic fluid by quantitative fluorescent polymerase chain reaction. J Med Genet 1998;35:126-129.

  48. Sun L, Fan Z, Long J, Weng X, Tang W, Pang W. Rapid prenatal diagnosis of aneuploidy for chromosomes 21, 18, 13, X, and Y using segmental duplication quantitative fluorescent PCR (SD-QF-PCR). Gene 2017;627:72-78.

  49. Vahab-Saadi A, Kushtagi P, Gopinath PM, Satyamoorthy K. Quantitative fluorescence polymerase chain reaction (QF-PCR) for prenatal diagnosis of chromosomal aneuploidies. Int J Hum Genet 2010;10:121-129.

  50. Samura O, Sohda S, Johnson KL, Pertl B, Ralston S, Delli-Bovi LC, et al. Diagnosis of trisomy 21 in fetal nucleated erythrocytes from maternal blood by use of short tandem repeat sequences. Clin Chem 2001;47:1622-1626.

  51. Pertl B, Yau SC, Sherlock J, Davies AF, Mathew CG, Adinolfi M. Rapid molecular method for prenatal detection of Down’s syndrome. Lancet 1994;343:1197-1198.

  52. Elsayed GM, El Assiouty L, El Sobky ES. The importance of rapid aneuploidy screening and prenatal diagnosis in the detection of numerical chromosomal abnormalities. Springerplus 2013;2:490.

  53. Slater HR, Bruno DL, Ren H, Pertile M, Schouten JP, Choo KH. Rapid, high throughput prenatal detection of aneuploidy using a novel quantitative method (MLPA). J Med Genet 2003;40:907-912.

  54. van Veghel-Plandsoen MM, Wouters CH, Kromosoeto JNR, den Ridder-Klünnen MC, Halley DJJ, van den Ouweland AMW. Multiplex ligation-depending probe amplification is not suitable for detection of low-grade mosaicism. Eur J Hum Genet 2011;19:1009-1012.

  55. Deutsch S, Choudhury U, Sylvan A, Antonarakis SE. Detection of trisomy 21 and other aneuploidies by paralogous gene quantification. Am J Hum Genet 2003 73:318.

  56. Ishkanian AS, Malloff CA, Watson SK, De- Leeuw RJ, Chi B, Coe BP, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36:299-303.

  57. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263- 264.

  58. Rodríguez-Santiago B, Armengol L. Tecnologías de secuenciación de nueva generación en diagnóstico genético pre-y postnatal. Diagn Prenat 2012;23:56-66.

  59. Nepomnyashchaya YN, Artemov AV, Roumiantsev SA, Roumyantsev AG, Zhavoronkov A. Non-invasive prenatal diagnostics of aneuploidy using next-generation DNA sequencing technologies, and clinical considerations. Clin Chem Lab Med 2013;51:1141-1154.

  60. Gekas J, Langlois S, Ravitsky V, Audibert F, van den Berg DG, Haidar H, et al. Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues. Appl Clin Genet 2016;9:15-26.




2020     |     www.medigraphic.com